Emerging From Restructuring, Zyomyx Rebrands Its Identity As Services Shop | GenomeWeb

Protein chip company Zyomyx has rebranded itself as a services company, creating a new business strategy after laying off 80 percent of its staff and auctioning off much of its equipment.

Instead of bringing its own products to market, Zyomyx will now seek to develop products and technologies on behalf of partners. The company will focus on proteomics, molecular diagnostics, medical devices and other industrial applications of its expertise.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.